Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)

NCT02419170 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Investigator who manufactured the vaccine left the university.

Conditions

Carcinoma, Non-Small-Cell-Lung
Non-Small Cell Lung Cancer
Nonsmall Cell Lung Cancer

Interventions

PROCEDURE: Standard of care surgery
PROCEDURE: Apheresis
DRUG: Cyclophosphamide
BIOLOGICAL: Personalized mature dendritic cell vaccine

Sponsor

Washington University School of Medicine